Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) have received an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Brokerages have set a 1-year consensus price target of $12.50 for the company and are forecasting that the company will post ($0.08) EPS for the current quarter, according to Zacks. Zacks has also given Anavex Life Sciences Corp. an industry rank of 105 out of 265 based on the ratings given to its competitors.
Several brokerages have recently issued reports on AVXL. FBR & Co reaffirmed a “buy” rating on shares of Anavex Life Sciences Corp. in a research report on Wednesday, June 22nd. Maxim Group set a $15.00 price target on Anavex Life Sciences Corp. and gave the company a “buy” rating in a research report on Wednesday, July 27th. Finally, Zacks Investment Research downgraded Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th.
Several large investors have recently added to or reduced their stakes in the stock. American International Group Inc. bought a new stake in Anavex Life Sciences Corp. during the second quarter valued at $115,000. Nationwide Fund Advisors bought a new stake in Anavex Life Sciences Corp. during the second quarter valued at $130,000. Rhumbline Advisers bought a new stake in Anavex Life Sciences Corp. during the second quarter valued at $192,000. Schwab Charles Investment Management Inc. bought a new stake in Anavex Life Sciences Corp. during the second quarter valued at $313,000. Finally, Teachers Advisors Inc. bought a new stake in Anavex Life Sciences Corp. during the second quarter valued at $314,000. Institutional investors and hedge funds own 10.71% of the company’s stock.
Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) traded down 1.48% during mid-day trading on Wednesday, reaching $3.32. The company’s stock had a trading volume of 285,141 shares. The company has a 50 day moving average price of $3.16 and a 200 day moving average price of $4.42. Anavex Life Sciences Corp. has a 12 month low of $2.43 and a 12 month high of $14.84. The stock’s market capitalization is $118.56 million.
Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its quarterly earnings results on Thursday, August 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. On average, equities research analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current fiscal year.
Anavex Life Sciences Corp. Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.